Roche’s Tecentriq wins speedy U.S. FDA review for small cell lung cancer

71

ZURICH (Reuters) – Swiss group Roche Holding AG said on Wednesday its Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals’ revenues.

The announcement comes after Roche in September said patients with untreated extensive-stage small cell lung cancer (SCLC) lived a median 12.3 months after getting the Tecentriq cocktail, compared to 10.3 months for those getting chemotherapy alone.

Winning the speedy review from the U.S. Food and Drug Administration sets up possible U.S. approval for Tecentriq in this indication by March 18, the drugmaker said in a statement.

 

More https://www.reuters.com/article/us-roche-tecentriq/roches-tecentriq-wins-speedy-u-s-fda-review-for-small-cell-lung-cancer-idUSKBN1O40GZ